JAMA Pediatrics,
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
This Viewpoint discusses controversies surrounding the US Food and Drug Administration's 2016 approval of eteplirsen for…
For now, eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies: demonstrate a…
http://jamanetwork.com/journals/jama/article-abstract/2572614